Biolegend, 655002, Purified anti-PTEN Antibody, 100μg

PTEN was discovered as a tumor suppressor with lipid and protein phosphatase activity. Heterozygous loss of PTEN in mice contribute to the development of a variety of types of cancer, suggesting that insufficient PTEN activity results in increased cancer susceptibility. PTEN negatively regulates the PI3K/AKT pathway by dephosphorylating the second messenger phosphoinositide 3,4,5-triphosphate (PIP3) produced by phosphoinositide 3-kinase (PI3K), which results in inhibition of abnormal cell proliferation. Despite the hydrolysis function of PIP3, the nuclear population of PTEN possesses greater tumor suppressive activities, regulates gene expression, differentiation, and cell cycle progression.
100μg
Verified Reactivity: Human, Mouse
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Partial human PTEN recombinant protein (303-403aa)
Formulation: This antibody is provided in phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.Previous lots of this product may have been formulated with 0.1% or 0.05% NaN3 instead of 0.09% NaN3. For further information please contact BioLegend Technical Support or Customer Service.
Preparation: Affinity purified.
Concentration: 0.5 mg/ml
Storage & Handling: Upon receipt, store undiluted between 2°C and 8°C.
Application: WB - Quality testedICC - Verified
Recommended Usage: Each lot of this antibody is quality control tested by Western blotting. For Western blotting, the suggested use of this reagent is 0.5 - 2.5 µg per ml. For immunocytochemistry, a concentration range of 2.5 - 5.0 µg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: The binding of PTEN antibody (4C11A11) to its target is sensitive to salt concentration. Please use the Biolegend recommended TBS/T buffer for Western blotting.
Product Citations: Lightle HE, et al. 2023. Methods. 95:219. PubMed Batth IS, et al. 2020. BMC Cancer. 20(1):715. PubMed Ren W, et al. 2019. J Exp Clin Cancer Res. 38:62. PubMed
RRID: AB_2561892 (BioLegend Cat. No. 655002)
Structure: 403 amino acids, predicted molecular weight of 47 kD, and observed molecular weight of 54 kD. Contains a C2 tensin-like domain responsible for lipid binding and membrane localization.
Distribution: Cytoplasm (unubiquitinated form); nucleus (mono-ubiquitinated form).
Function: PTEN functions as a tumor suppressor, modulating the PI3K-AKT-mTOR signaling pathway. It exerts phosphatase activity, dephosphorylating serine, threonine, and tyrosine phosphorylated proteins. In addition, dephosphorylates phospholipids, removing a phosphate from phosphatidylinositol-3,4,5-trisphosphate. The lipid phosphatase activity is required for its tumor suppressor function.
Interaction: Interacts with MAIG2, MAIG3, MAST1, MAST3, NEDD4, NDFIP1, NDFIP2, USP7, ROCK1, and XIAP. The unphosphorylated form interacts with AIP1, DLG1 and MAS.T2.
Biology Area: Angiogenesis, Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Cell Cycle/DNA Replication, Signal Transduction, Transcription Factors
Molecular Family: Protein Kinases/Phosphatase
Antigen References: 1. Carracedo A, et al. 2011. Cancer Res. 71:629. 2. Jiang BH and Liu LZ. 2009. Adv Cancer Res. 102:19. 3. Mao JH, et al. 2008. Science 321:1499. 4. Weng LP, et al. 2001. Hum. Mol. Genet. 10:599. 5. Wrighton KH. 2011. Nat Rev Cancer. 11:154. 6. Wang X, et al. 2007. Cell 128:129.
Gene ID: 5728
UniProt: View information about PTEN on UniProt.org
Clone: 4C11A11
Regulatory Status: RUO
Other Names: MMAC1, BZS, TEP1, MHAM1, GLM2, PTEN1
Isotype: Mouse IgG2b, κ